NOVYRA
PHARMACHEM LIMITED

CIN NO. :- L21001GJ1987PLC171085

August 14, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: - 519353

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on August 14, 2026
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held on today i.e. Friday, August 14, 2026 at the Registered Office of the Company ***inter-alia*** has, considered and approved the following: -

1. Un-Audited Financial Results of the Company for the Quarter ended June 30, 2026, along with Auditors' Limited Reports, in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.

2. Reviewed the business of the company.

The Board Meeting commenced at 05:30 P.M. and concluded at 06:00 p.m.

You are requested to take the above information on records and disseminate the same on your respective websites.

Thanking you,
Yours faithfully,

For, Novyra Pharmachem Limited
(formerly known as Bansisons Tea Industries Ltd)
For, Novyra Pharmachem Limited

Anil M. Amreliya

Director/Autho. Signatory
Anilkumar Mohanbhai Amreliya
Director
DIN : 11339148

NOVYRA PHARMACHEM LIMITED

R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004

CIN : L21001GJ1987PLC171085

Reporting of Segment wise Revenue, Results and Capital Employed along financial results for the Quarter Ended on June 30, 2026

(` In Lakh except per share data)

	Particulars	Quarter Ended			For The Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
A	Date of start of reporting period	01/04/2026	01/01/2026	01/04/2025	01/04/2025
B	Date of end of reporting period	30/06/2026	31/03/2026	30/06/2025	31/03/2026
C	Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Segment Revenue** (net sale/income from each segment should be disclosed under this head)				
(a)	Segment - Pharma	172.61	1.00	-	1.00
(b)	Segment - Real Estate	-	0.50	-	3.50
(c)	Segment - Tea Estate	-	8.94	-	12.25
(d)	Segment - Unallocable	-	-	3.00	-
					-
	Total	**172.61**	**10.44**	**3.00**	**16.75**
	Less: Inter Segment Revenue		-	-	-
	Net sales/Income From Operations	**172.61**	**10.44**	**3.00**	**16.75**
2	**Segment Results (Profit)(+)/ Loss (-) before tax and interest from Each segment)#**				
(a)	Segment - Pharma	1.29	1.00		1.00
(b)	Segment - Real Estate	-	0.50	-	3.50
(c)	Segment - Tea Estate	-	(449.39)	-	(446.64)
(d)	Segment - Unallocable	(3.28)	(85.38)	(0.77)	(95.24)
					-
	Total	**(1.99)**	**(533.27)**	**(0.77)**	**(537.38)**
	Less:	-	-	-	-
	Finance Cost	-			
	Other Un-allocable Expenditure net off	-		-	
	Un-allocable income		-	-	
	Total Profit Before Tax	**(1.99)**	**(533.27)**	**(0.77)**	**(537.38)**
					-
3	**Capital Employed (Segment assets - Segment Liabilities)**				
3(1)	**Segment Assets**				
(a)	Segment - Pharma	197.39	1.08	-	1.08
(b)	Segment - Real Estate	21.02	44.27	13.74	44.27
(c)	Segment - Tea Estate	97.03	140.41	549.16	74.09
(d)	Segment - Unallocable	16.75	26.44	53.44	26.44
	Total	**332.19**	**212.20**	**616.34**	**145.88**
3(2)	**Segment Liabilities**				
(a)	Segment - Pharma	280.19	82.34	82.34	82.34
(b)	Segment - Real Estate	-		-	
(c)	Segment - Tea Estate	-		(0.36)	
(d)	Segment - Unallocable	(8.21)	4.34	22.84	4.34
	Total	**271.98**	**86.68**	**104.82**	**86.68**

FOR NOVYRA PHARMACHEM LIMITED

For, Novyra Pharmachem Limited

Anil M Amreliya

Director/Autho. Signatory

Anilkumar Mohanbhai Amreliya

Director

DIN: 11339148

Date :- 14-08-2026

Place :- Surat

NOVYRA PHARMACHEM LIMITED

R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004

CIN : L21001GJ1987PLC171085

Statement of unaudited Standalone Financial Results for the Quarter ended June 30, 2026

(Rs. In Lakhs)

	Particulars	Quarter Ended			For The Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
A	Date of start of reporting period	01/04/2026	01/01/2026	01/04/2025	01/04/2025
B	Date of end of reporting period	30/06/2026	31/03/2026	30/06/2025	31/03/2026
C	Whether results are audited or unaudited	Unaudited	Audited	Audited	Audited
	Revenue From Operations				
	(a) Revenue From Operations	172.61	10.44	-	10.44
	(b) Other Income	-	-	3.00	6.31
	Total Revenue from operations (net)	**172.61**	**10.44**	**3.00**	**16.75**
		-			
	Expenditure	-			
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	189.13	-	-	-
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	-17.81	-	-	-
	(d) Employee benefit expense	0.60	11.80	1.41	15.06
	(e) Finance Costs	-	-	-	-
	(e) Depreciation and amortisation expense	0.30	0.73	0.72	2.89
	(f) Other Expenses	2.38	531.73	1.64	536.17
		-			
	Total expenses	**174.60**	**544.26**	**3.77**	**554.12**
	Profit (loss) Before exceptional & Extraordinary items and Tax	**(1.99)**	**(533.83)**	**(0.77)**	**(537.38)**
	Exceptional items	-			
	Profit (loss) from ordinary activities before tax	**(1.99)**	**(533.83)**	**(0.77)**	**(537.38)**
	Tax Expenses - Current Tax	-	-		
	(less):- MAT Credit	-	-	-	-
	Current Tax Expense Relating to Prior years	-	-	-	-
	Deferred Tax (Assets)/liabtiltles				
	Profit (loss) from ordinary activities	**(1.99)**	**(533.83)**	**(0.77)**	**(537.38)**
	Other Comprehensive Income (OCI)	-			
		-			
	Items that will not be reclassified to profit or loss	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or	-	-	-	-
		-	-	-	-
	Items that will be reclassified to profit or loss	-	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
		-			
	Total Profit After Other Comprehensive Income	**(1.99)**	**(533.83)**	**(0.77)**	**(537.38)**
	Profit/(Loss) From Discountinuing Operation Before Tax	-			
	Tax Expenses of Discontinuing Operations	-			
	Net Profit/(Loss) from Discountinuing Opration After Tax	-	-	-	-
	Profit(Loss) For Period Before Minority Interest	-	-	-	-
	Share Of Profit / Loss Associates	-			
	Profit/Loss Of Minority Interset	-			
	Net Profit (+)/ Loss (-) For the Period	**(1.99)**	**(533.83)**	**(0.77)**	**(537.38)**
	Details of equity share capital				
	Paid-up equity share capital	633.00	633.00	630.00	633.00
	Face value of equity share capital (per share)	10.00	10.00	10.00	10.00

	Reserve Excluding Revaluation Reserves As Par Balance sheet Of previous Year		-	-	-
	Earnings per share (EPS)				
	Basic earnings per share from countinuing And Discountinuing operations	(0.03)	(8.43)	(0.01)	(8.49)
	Diluted earnings per share from countinuing And Discountinuing operations	(0.03)	(8.43)	(0.01)	(8.49)

Notes:-

1	The above said finanical results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective Meetings held on 14th August , 2026.
2	The Statutory Auditors have carried out limited review of the Unaudited Results of the Compnay for the Quarter ended 30/06/2026.
3	These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.
4	The Company has three reportable business segment(Pharma, Real Estate & Tea Estate). Hence, separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".

For, Novyra Pharmachem Limited

FOR NOVYRA PHARMACHEM LIMITED

Anil M Amreliya

Director/Autho. Signatory

Date :-14-08-2026

Place :- SURAT

UDIN :-26115279VCBPFZ1372

Anilkumar Mohanbhai Amreliya

Director

DIN: 11339148

D G M S & Co.
Chartered Accountants

Hiren J. Maru
B.Com., F.C.A., DISA, DIRM

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended)

To Board of Directors of
NOVYRA PHARMACHEM LIMITED
(Formerly known as Bansisons Tea Industries Limited)

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results **Novyra Pharmachem Limted (Formerly known as Bansisons Tea Industries Limited)** ("the Company") for the quarter ended 30th June 2026 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors at their meeting held on **14th August 2026**, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" (Ind AS 34), as prescribed under section 133 of the Companies Act, 2013 as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review of the Statement conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.
Chartered Accountants
Firm Regn. No. 0112187W

D G M S & CO. ★ Chartered Accountants ★ FRN: 0112187W

Hiren Maru
Partner
Membership No. 115279
UDIN: 26115279VCBPFZ1372
Date: 14th August 2026
Place: Mumbai